Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) CFO Nick Pizzie sold 3,000 shares of the business's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Axsome Therapeutics Stock Performance
NASDAQ:AXSM opened at $131.15 on Friday. Axsome Therapeutics, Inc. has a twelve month low of $64.11 and a twelve month high of $134.18. The company has a market cap of $6.36 billion, a P/E ratio of -20.08 and a beta of 1.05. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97. The company's 50-day moving average price is $97.84 and its 200-day moving average price is $93.27.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The business had revenue of $104.76 million for the quarter, compared to analysts' expectations of $98.71 million. During the same period in the previous year, the firm posted ($1.32) EPS. On average, sell-side analysts forecast that Axsome Therapeutics, Inc. will post -4.7 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on AXSM. Mizuho lifted their price target on Axsome Therapeutics from $137.00 to $195.00 and gave the stock an "outperform" rating in a research report on Tuesday. William Blair reiterated an "outperform" rating on shares of Axsome Therapeutics in a research report on Friday, January 24th. HC Wainwright reissued a "buy" rating and set a $190.00 price target on shares of Axsome Therapeutics in a research report on Tuesday. Wells Fargo & Company boosted their target price on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the company an "overweight" rating in a research report on Wednesday. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $139.00 price objective on shares of Axsome Therapeutics in a research report on Wednesday, January 29th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $147.13.
Check Out Our Latest Research Report on AXSM
Institutional Trading of Axsome Therapeutics
Several large investors have recently added to or reduced their stakes in AXSM. JPMorgan Chase & Co. boosted its position in shares of Axsome Therapeutics by 14.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company's stock valued at $19,062,000 after acquiring an additional 27,534 shares during the last quarter. Strategic Financial Concepts LLC purchased a new stake in shares of Axsome Therapeutics in the 4th quarter valued at approximately $2,599,000. PDT Partners LLC acquired a new stake in shares of Axsome Therapeutics during the 3rd quarter worth approximately $1,052,000. Pallas Capital Advisors LLC purchased a new stake in shares of Axsome Therapeutics during the 4th quarter valued at approximately $2,237,000. Finally, Captrust Financial Advisors acquired a new position in Axsome Therapeutics in the third quarter valued at approximately $514,000. 81.49% of the stock is currently owned by hedge funds and other institutional investors.
Axsome Therapeutics Company Profile
(
Get Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
